Short answer
ZEVRA THERAPEUTICS, INC. (ZVRA) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $40M (up 53.3% year over year) with net income of $9M.
Q2 2026 key financials · XBRL
- Revenue
- $40M
- +53.3% YoY · +9.5% QoQ
- Net income
- $9M
- −88.3% YoY · −76.9% QoQ
- Operating margin
- 42.3%
- EPS (diluted)
- $0.14
- −88.5% YoY · −76.7% QoQ
Source: XBRL data from the ZEVRA THERAPEUTICS, INC. (ZVRA) Q2 2026 10-Q on SEC EDGAR. USD.
ZEVRA THERAPEUTICS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $39.7M, up $13.8M YoY from $25.9M, driven by MIPLYFFA sales up $8.7M
- Operating income $16.8M vs $71.0M operating loss YoY
- MIPLYFFA best-performing product, with product sales up $8.7M; OLPRUVA revenue $0.2M
- Operating cash flow $23.2M vs $(11.8)M YoY for six months ended June 30
- EMA CHMP negative opinion on arimoclomol; re-examination requested, while OLPRUVA sales and marketing scaled back
Risk Factors
- No material changes to risk factors from the most recent 10-K
- Carried-forward risks remain applicable without quarterly updates
- Rule 10b5-1 plan for up to 42,666 shares adopted by Chief Legal Officer
- Plan termination scheduled for December 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ZEVRA THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.